Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353375 | 0.93 | MTNR1A (0.65) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16898561 | 0.89 | MTNR1A (0.60) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| Cyclopropane SCHEMBL9509777 | 0.88 | RAB9A (0.61) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10828184 | 0.88 | L3MBTL1 (0.66) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25268781 | 0.86 | MAPT (0.60) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11312884 | 0.86 | GAA (0.66) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11318404 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21595955 | 0.85 | NPC1 (0.73) | MTNR1AMTNR1BNPC1SMN1; SMN2HPGD | |
| SCHEMBL885015 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25268396 | 0.85 | DRD4 (0.57) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895482-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | claimed |
| US-9315475-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | claimed |
| EP-2895482-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-07-22 | — | — | EP | claimed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | claimed |
| WO-2014043019-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-03-20 | — | — | WO | claimed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| EP-2895482-B1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9315475-B2 | HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2010007482-A2 | THIAZOLE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
| US-4745128-A | INSECTICIDES, MITICIDES | INNOFINANCE ALTALANOS INNOVACIOS PENZINTEZET (HU) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | MTNR1A 1512/4885MTNR1B 1744/4885RAB9A 3678/4885 |
| US-20140200197-A1 | HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | MTNR1A 4669/4885MTNR1B 4628/4885RAB9A 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.